Danaher Corporation Schedules Q2 2026 Earnings Conference Call
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Source: PRnewswire
- Earnings Call Schedule: Danaher Corporation will hold its Q2 2026 earnings conference call on July 21, 2026, at 8:00 a.m. ET, lasting approximately one hour, during which the company will discuss its financial performance and future expectations.
- Webcast Information: The call and accompanying slides will be webcast on the 'Investors' section of Danaher's website, enhancing transparency and allowing investors to access real-time information.
- Replay Availability: A replay of the conference call will be available shortly after the conclusion and will remain accessible until August 4, 2026, ensuring that investors who cannot attend live can still obtain key insights.
- Earnings Materials Release: Danaher will post its earnings press release and related materials at 6:00 a.m. on the day of the call, further enhancing investor understanding and engagement with the company's performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DHR
Wall Street analysts forecast DHR stock price to rise
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 193.210
Low
240.00
Averages
266.18
High
310.00
Current: 193.210
Low
240.00
Averages
266.18
High
310.00
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services. The Company also provides pulse oximetry and other patient monitoring solutions, primarily in acute care treatment settings.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Danaher's Masimo Acquisition Raises Concerns Amid Growth Potential
- Acquisition Potential: Danaher's $9.9 billion acquisition of Masimo raises patent dispute concerns but is expected to add $0.15 to $0.20 to adjusted EPS in the first year, scaling to $0.70 by year five, indicating significant future growth potential.
- First Quarter Recovery: In Q1, Danaher reported revenue of $5.95 billion, a 3% year-over-year increase, with EPS at $1.45, up 9.8%, demonstrating financial resilience despite a 22% stock price decline this year.
- Significant Order Growth: The company noted a 30% year-over-year increase in equipment orders, signaling the start of a multi-year manufacturing investment cycle, bolstered by reshoring trends and renewed interest in the life sciences sector.
- Low Market Valuation: Despite execution risks, Danaher's stock trades at just over 20 times forward earnings, significantly below its typical valuation over the past decade, suggesting that if management successfully integrates Masimo, the current stock price may be undervalued.
See More
Danaher's Masimo Acquisition Raises Concerns Amid Stock Decline
- Acquisition Impact: Danaher's $9.9 billion acquisition of Masimo is expected to boost adjusted EPS by $0.15 to $0.20 in the first year, yet it raises concerns over patent disputes with Apple and increased debt levels.
- Financial Performance: In Q1 2023, Danaher reported revenues of $5.95 billion, a 3% year-over-year increase, with EPS at $1.45, reflecting a 9.8% growth, demonstrating resilience amid challenges.
- Market Dynamics: The U.S. pharma and life sciences sector saw M&A activity exceed $65 billion in Q1 2026, nearly doubling the previous year's total, indicating large pharmaceutical companies are seeking acquisitions to enhance their pipelines, which could benefit Danaher's equipment sales.
- Future Outlook: Despite the execution risks of integrating Masimo, Danaher raised its 2026 EPS guidance to a range of $8.35 to $8.55, indicating confidence in future growth, although the market remains cautious about the stock's rebound potential.
See More
Profitable Stocks with Promising Prospects and Underwhelming Performers
- Flowers Foods Struggles: Flowers Foods (FLO) has seen unit sales decline over the past two years, with projected sales dropping by 1.9% in the next 12 months, indicating a need for product improvements to regain growth, while a 21.7% annual drop in earnings per share threatens its profitability.
- Danaher Faces Challenges: Danaher (DHR) has experienced a 10.6 percentage point decline in operating margin over the past five years, as rising costs outpace revenue growth, resulting in flat earnings per share compared to peers; its current share price of $178.03 reflects a forward P/E of 20.4, highlighting investment risks.
- Coinbase Worth Watching: Coinbase (COIN) achieved an impressive 28.5% annual revenue growth over the last two years, indicating market share gains, with a best-in-class gross margin of 85.9% and a robust free cash flow margin of 35.2%, trading at $164.58 per share with a forward EV/EBITDA of 15.2.
- Market Dynamics Shift: While Flowers Foods and Danaher face growth challenges, Coinbase's strong performance suggests that high-quality stocks can still attract investor interest amid changing market conditions, reflecting ongoing demand for premium companies.
See More
Danaher Corporation Schedules Q2 2026 Earnings Conference Call
- Earnings Call Schedule: Danaher Corporation will hold its Q2 2026 earnings conference call on July 21, 2026, at 8:00 a.m. ET, lasting approximately one hour, during which the company will discuss its financial performance and future expectations.
- Webcast Information: The call and accompanying slides will be webcast on the 'Investors' section of Danaher's website, enhancing transparency and allowing investors to access real-time information.
- Replay Availability: A replay of the conference call will be available shortly after the conclusion and will remain accessible until August 4, 2026, ensuring that investors who cannot attend live can still obtain key insights.
- Earnings Materials Release: Danaher will post its earnings press release and related materials at 6:00 a.m. on the day of the call, further enhancing investor understanding and engagement with the company's performance.
See More
Investment Opportunities in the Healthcare Sector
- Healthcare Spending Growth: U.S. healthcare spending is projected to reach nearly $5.3 trillion in 2024, indicating long-term growth potential in the sector, making stocks like CRISPR, Zoetis, and Danaher attractive for investors.
- CRISPR's Innovation Potential: CRISPR Therapeutics leads in gene editing, with its FDA-approved Casgevy treatment expected to boost sales from $36 million to $145 million, presenting a volatile yet promising long-term investment opportunity.
- Zoetis Market Rebound: Despite negative publicity from Librela, Zoetis trades at a low P/E of 11 compared to its historical average of 37, with analysts forecasting a 9% annual growth over the next three years, offering a compelling investment case.
- Danaher's Acquisition Strategy: Danaher recently acquired Masimo for $9.9 billion, enhancing its position in pulse oximetry technology; despite a 40% drop from its peak, the stock's future growth potential remains strong and appealing to investors.
See More
Masimo Receives FDA Clearance for New Respiratory Monitoring Technology
- FDA Approval for New Feature: Masimo's Radius VSM® wearable monitor has received FDA 510(k) clearance for its opioid-induced respiratory depression (OIRD) detection capability, which will assist clinicians in identifying respiratory risks earlier, thereby enhancing patient safety within hospitals.
- Smart Sensor Application: This feature leverages Masimo's smartSET™ pulse oximetry sensor platform to analyze continuous physiological data, providing earlier clinical awareness that supports faster, more informed decisions when a patient's condition is rapidly deteriorating, significantly improving monitoring effectiveness.
- Enhanced Monitoring Capability: The introduction of the OIRD detection feature not only strengthens the monitoring capabilities of Radius VSM but also includes a visual alarm system that alerts clinicians to changes in patient condition, ensuring rapid response during critical situations and further improving care quality in hospitals.
- Future Development Potential: Masimo plans to develop additional pattern recognition algorithms for the smartSET platform, aiming to translate this technology into broader hospital monitoring solutions, thereby advancing the application of continuous monitoring technology across various care environments and enhancing overall patient care standards.
See More
Danaher's Masimo Acquisition Raises Concerns Amid Growth Potential
- Acquisition Potential: Danaher's $9.9 billion acquisition of Masimo raises patent dispute concerns but is expected to add $0.15 to $0.20 to adjusted EPS in the first year, scaling to $0.70 by year five, indicating significant future growth potential.
- First Quarter Recovery: In Q1, Danaher reported revenue of $5.95 billion, a 3% year-over-year increase, with EPS at $1.45, up 9.8%, demonstrating financial resilience despite a 22% stock price decline this year.
- Significant Order Growth: The company noted a 30% year-over-year increase in equipment orders, signaling the start of a multi-year manufacturing investment cycle, bolstered by reshoring trends and renewed interest in the life sciences sector.
- Low Market Valuation: Despite execution risks, Danaher's stock trades at just over 20 times forward earnings, significantly below its typical valuation over the past decade, suggesting that if management successfully integrates Masimo, the current stock price may be undervalued.
See More
Danaher's Masimo Acquisition Raises Concerns Amid Stock Decline
- Acquisition Impact: Danaher's $9.9 billion acquisition of Masimo is expected to boost adjusted EPS by $0.15 to $0.20 in the first year, yet it raises concerns over patent disputes with Apple and increased debt levels.
- Financial Performance: In Q1 2023, Danaher reported revenues of $5.95 billion, a 3% year-over-year increase, with EPS at $1.45, reflecting a 9.8% growth, demonstrating resilience amid challenges.
- Market Dynamics: The U.S. pharma and life sciences sector saw M&A activity exceed $65 billion in Q1 2026, nearly doubling the previous year's total, indicating large pharmaceutical companies are seeking acquisitions to enhance their pipelines, which could benefit Danaher's equipment sales.
- Future Outlook: Despite the execution risks of integrating Masimo, Danaher raised its 2026 EPS guidance to a range of $8.35 to $8.55, indicating confidence in future growth, although the market remains cautious about the stock's rebound potential.
See More
Profitable Stocks with Promising Prospects and Underwhelming Performers
- Flowers Foods Struggles: Flowers Foods (FLO) has seen unit sales decline over the past two years, with projected sales dropping by 1.9% in the next 12 months, indicating a need for product improvements to regain growth, while a 21.7% annual drop in earnings per share threatens its profitability.
- Danaher Faces Challenges: Danaher (DHR) has experienced a 10.6 percentage point decline in operating margin over the past five years, as rising costs outpace revenue growth, resulting in flat earnings per share compared to peers; its current share price of $178.03 reflects a forward P/E of 20.4, highlighting investment risks.
- Coinbase Worth Watching: Coinbase (COIN) achieved an impressive 28.5% annual revenue growth over the last two years, indicating market share gains, with a best-in-class gross margin of 85.9% and a robust free cash flow margin of 35.2%, trading at $164.58 per share with a forward EV/EBITDA of 15.2.
- Market Dynamics Shift: While Flowers Foods and Danaher face growth challenges, Coinbase's strong performance suggests that high-quality stocks can still attract investor interest amid changing market conditions, reflecting ongoing demand for premium companies.
See More
Danaher Corporation Schedules Q2 2026 Earnings Conference Call
- Earnings Call Schedule: Danaher Corporation will hold its Q2 2026 earnings conference call on July 21, 2026, at 8:00 a.m. ET, lasting approximately one hour, during which the company will discuss its financial performance and future expectations.
- Webcast Information: The call and accompanying slides will be webcast on the 'Investors' section of Danaher's website, enhancing transparency and allowing investors to access real-time information.
- Replay Availability: A replay of the conference call will be available shortly after the conclusion and will remain accessible until August 4, 2026, ensuring that investors who cannot attend live can still obtain key insights.
- Earnings Materials Release: Danaher will post its earnings press release and related materials at 6:00 a.m. on the day of the call, further enhancing investor understanding and engagement with the company's performance.
See More
Investment Opportunities in the Healthcare Sector
- Healthcare Spending Growth: U.S. healthcare spending is projected to reach nearly $5.3 trillion in 2024, indicating long-term growth potential in the sector, making stocks like CRISPR, Zoetis, and Danaher attractive for investors.
- CRISPR's Innovation Potential: CRISPR Therapeutics leads in gene editing, with its FDA-approved Casgevy treatment expected to boost sales from $36 million to $145 million, presenting a volatile yet promising long-term investment opportunity.
- Zoetis Market Rebound: Despite negative publicity from Librela, Zoetis trades at a low P/E of 11 compared to its historical average of 37, with analysts forecasting a 9% annual growth over the next three years, offering a compelling investment case.
- Danaher's Acquisition Strategy: Danaher recently acquired Masimo for $9.9 billion, enhancing its position in pulse oximetry technology; despite a 40% drop from its peak, the stock's future growth potential remains strong and appealing to investors.
See More
Masimo Receives FDA Clearance for New Respiratory Monitoring Technology
- FDA Approval for New Feature: Masimo's Radius VSM® wearable monitor has received FDA 510(k) clearance for its opioid-induced respiratory depression (OIRD) detection capability, which will assist clinicians in identifying respiratory risks earlier, thereby enhancing patient safety within hospitals.
- Smart Sensor Application: This feature leverages Masimo's smartSET™ pulse oximetry sensor platform to analyze continuous physiological data, providing earlier clinical awareness that supports faster, more informed decisions when a patient's condition is rapidly deteriorating, significantly improving monitoring effectiveness.
- Enhanced Monitoring Capability: The introduction of the OIRD detection feature not only strengthens the monitoring capabilities of Radius VSM but also includes a visual alarm system that alerts clinicians to changes in patient condition, ensuring rapid response during critical situations and further improving care quality in hospitals.
- Future Development Potential: Masimo plans to develop additional pattern recognition algorithms for the smartSET platform, aiming to translate this technology into broader hospital monitoring solutions, thereby advancing the application of continuous monitoring technology across various care environments and enhancing overall patient care standards.
See More
